Tyrosine

Tyrosine

SCHEMBL638520

N[C@@H](Cc1ccc(O)cc1)C(=O)O.OO

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 3/20 1.00
PTGS1 P23219 3/20 0.70
ALPI P09923 1/20 0.70
PKM P14618 1/20 0.70
XIAP P98170 1/20 0.70
ALOX15 P16050 3/20 0.65
HIF1A Q16665 3/20 0.65
KDM4E B2RXH2 2/20 0.65
TDP1 Q9NUW8 2/20 0.65
USP2 O75604 1/20 0.65
EGFR P00533 1/20 0.65
LCK P06239 1/20 0.65
FYN P06241 1/20 0.65
ADORA3 P0DMS8 1/20 0.65
HTR2A P28223 1/20 0.65
PTGS2 P35354 1/20 0.65
RECQL P46063 1/20 0.65
HSD17B10 Q99714 1/20 0.65
TPH1 P17752 1/20 0.59
GRB2 P62993 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tyrosine SCHEMBL10978805 1.00 SLC7A5 (1.00) SLC7A5PTGS1ALPIPKMXIAP
Tyrosine SCHEMBL11676395 1.00 SLC7A5 (1.00) SLC7A5PTGS1ALPIPKMXIAP
Tyrosine SCHEMBL11520027 1.00 SLC7A5 (1.00) SLC7A5PTGS1ALPIPKMXIAP
Tyrosine SCHEMBL10978820 1.00 SLC7A5 (1.00) SLC7A5PTGS1ALPIPKMXIAP
Tyrosine SCHEMBL1580 1.00 SLC7A5 (1.00) SLC7A5PTGS1ALPIPKMXIAP
Tyrosine SCHEMBL20787 1.00 SLC7A5 (1.00) SLC7A5PTGS1ALPIPKMXIAP
Tyrosine SCHEMBL11520041 1.00 SLC7A5 (1.00) SLC7A5PTGS1ALPIPKMXIAP
Tyrosine SCHEMBL1581 1.00 SLC7A5 (1.00) SLC7A5PTGS1ALPIPKMXIAP
Tyrosine SCHEMBL11676367 1.00 SLC7A5 (1.00) SLC7A5PTGS1ALPIPKMXIAP
Tyrosine SCHEMBL30081492 1.00 SLC7A5 (1.00) SLC7A5PTGS1ALPIPKMXIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120264825-A1 Amino Acid Perhydrates, Process for Their Preparation and Uses thereof YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) 2012-10-18 US claimed
WO-2010128514-A1 AMINO ACID PERHYDRATES, PROCESS FOR THEIR PREPARATION AND USES THEREOF YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD (IL) 2010-11-11 WO claimed
CN-108478852-A A kind of pharmaceutical products, the carrier for loading pharmaceutical products, hydrogel and its method 湖北工程学院 2018-09-04 CN disclosed
EP-2306192-B1 Risk Markers For Cardiovascular Disease CLEVELAND CLINIC FOUNDATION (US) 2015-10-14 EP disclosed
US-9005904-B2 Risk markers for cardiovascular disease THE CLEVELAND CLINIC FOUNDATION (US) 2015-04-14 US disclosed
US-20150037905-A1 RISK MARKERS FOR CARDIOVASCULAR DISEASE THE CLEVELAND CLINIC FOUNDATION (US) 2015-02-05 US disclosed
US-8722344-B2 Risk markers for cardiovascular disease THE CLEVELAND CLINIC FOUNDATION (US) 2014-05-13 US disclosed
US-20130177551-A1 RISK MARKERS FOR CARDIOVASCULAR DISEASE HAZEN STANLEY L (US) 2013-07-11 US disclosed
US-8338110-B2 determining levels of one or more oxidized apolipoprotien A-I related biomolecules in a bodily sample; atherosclerosis THE CLEVELAND CLINIC FOUNDATION (US) 2012-12-25 US disclosed
US-20120264825-A1 Amino Acid Perhydrates, Process for Their Preparation and Uses thereof YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) 2012-10-18 US disclosed
EP-1697746-B1 RISK MARKERS FOR CARDIOVASCULAR DISEASE CLEVELAND CLINIC FOUNDATION (US) 2012-02-22 EP disclosed
EP-2306192-A2 Risk Markers For Cardiovascular Disease The Cleveland Clinic Foundation (US) 2011-04-06 EP disclosed
WO-2010128514-A1 AMINO ACID PERHYDRATES, PROCESS FOR THEIR PREPARATION AND USES THEREOF YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD (IL) 2010-11-11 WO disclosed
US-7781219-B2 determining levels of one or more oxidized apolipoprotien A-I related biomolecules in a bodily sample; atherosclerosis THE CLEVELAND CLINIC FOUNDATION (US) 2010-08-24 US disclosed
US-20100183607-A1 RISK MARKERS FOR CARDIOVASCULAR DISEASE THE CLEVELAND CLINIC FOUNDATION (US) 2010-07-22 US disclosed
EP-1697746-A4 RISK MARKERS FOR CARDIOVASCULAR DISEASE CLEVELAND CLINIC FOUNDATION (US) 2007-08-29 EP disclosed
EP-1697746-A2 RISK MARKERS FOR CARDIOVASCULAR DISEASE The Cleveland Clinic Foundation (US) 2006-09-06 EP disclosed
US-20050239136-A1 Risk markers for cardiovacular disease THE CLEVELAND CLINIC FOUNDATION 2005-10-27 US disclosed
WO-2005055810-A2 RISK MARKERS FOR CARDIOVASCULAR DISEASE THE CLEVELAND CLINIC FOUNDATION (US) 2005-06-23 WO disclosed